Kaerus Bioscience

Activities: Research & Development Digital

Trending Articles

  1. NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant...
  2. Isopod Rapid Cleanrooms: the ideal elite controlled environment pod solution for Life Sciences and Engineering start-ups The Guardtech Group’s quick-assembly cleanroom pods combine superior performance, build quality and cost-effectiveness to give new applications the perfect platform to get...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Delivering precision: why advanced therapies are redefining pharmaceutical logistics As advanced therapies narrow tolerances and personalise care, pharmaceutical logistics is being redefined as a precision-driven extension of treatment delivery, writes Michael...
  4. Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic...
  5. AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery...

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

Related Content

Research & Development

Servier acquires potential treatment for Fragile X syndrome

KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
Research & Development

Neurolentech partners with Kaerus Bioscience to advance neurodevelopmental disorder research

Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes
Subscribe now